Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy

Jiansheng Wang, Jia Zhang, Junping Sun, Jiangli Han, Yutao Xi, Geru Wu, Kristina X. Duan, Mingxin Zhang, Suna Zhou, Qi Liu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Prostacyclin (PGI2) and its analogues protect from cardiovascular disease through pleiotropic effects such as vasodilation, inhibition of platelet aggregation, leukocyte adhesion, and vascular smooth muscle cell (VSMC) proliferation. Additionally, prostacyclin synthase (PGIS) and PGI2 also possess anti-cancer properties. As of late (2009-2010), numerous studies have identified the deleterious side-effects of chemotherapy on the cardiovascular system, which have been deemed as a serious clinical issue. Cardiomyocyte damage, induced by oxidative stress, is one of the clinical consequences caused by routine cancer chemotherapy. Previous studies indicate iloprost, a PGI2 analogue, can protect against doxorubicin-induced (DOX) cardiomyocyte injury in vitro and in vivo without compromising tumor suppression. Therefore, we hypothesize PGI2 can be used as a cardioprotective supplement to attenuate the damaging cardiac effects caused by the traditional cancer chemotherapy regimen.

Original languageEnglish (US)
Pages (from-to)695-696
Number of pages2
JournalMedical Hypotheses
Volume76
Issue number5
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

Epoprostenol
Drug Therapy
Neoplasms
Cardiac Myocytes
Iloprost
Cardiovascular System
Platelet Aggregation
Vascular Smooth Muscle
Vasodilation
Doxorubicin
Smooth Muscle Myocytes
Oxidative Stress
Leukocytes
Cardiovascular Diseases
Cell Proliferation
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy. / Wang, Jiansheng; Zhang, Jia; Sun, Junping; Han, Jiangli; Xi, Yutao; Wu, Geru; Duan, Kristina X.; Zhang, Mingxin; Zhou, Suna; Liu, Qi.

In: Medical Hypotheses, Vol. 76, No. 5, 01.05.2011, p. 695-696.

Research output: Contribution to journalArticle

Wang, J, Zhang, J, Sun, J, Han, J, Xi, Y, Wu, G, Duan, KX, Zhang, M, Zhou, S & Liu, Q 2011, 'Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy', Medical Hypotheses, vol. 76, no. 5, pp. 695-696. https://doi.org/10.1016/j.mehy.2011.01.036
Wang, Jiansheng ; Zhang, Jia ; Sun, Junping ; Han, Jiangli ; Xi, Yutao ; Wu, Geru ; Duan, Kristina X. ; Zhang, Mingxin ; Zhou, Suna ; Liu, Qi. / Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy. In: Medical Hypotheses. 2011 ; Vol. 76, No. 5. pp. 695-696.
@article{3eff40c8dea34bca89b5b7a632294f99,
title = "Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy",
abstract = "Prostacyclin (PGI2) and its analogues protect from cardiovascular disease through pleiotropic effects such as vasodilation, inhibition of platelet aggregation, leukocyte adhesion, and vascular smooth muscle cell (VSMC) proliferation. Additionally, prostacyclin synthase (PGIS) and PGI2 also possess anti-cancer properties. As of late (2009-2010), numerous studies have identified the deleterious side-effects of chemotherapy on the cardiovascular system, which have been deemed as a serious clinical issue. Cardiomyocyte damage, induced by oxidative stress, is one of the clinical consequences caused by routine cancer chemotherapy. Previous studies indicate iloprost, a PGI2 analogue, can protect against doxorubicin-induced (DOX) cardiomyocyte injury in vitro and in vivo without compromising tumor suppression. Therefore, we hypothesize PGI2 can be used as a cardioprotective supplement to attenuate the damaging cardiac effects caused by the traditional cancer chemotherapy regimen.",
author = "Jiansheng Wang and Jia Zhang and Junping Sun and Jiangli Han and Yutao Xi and Geru Wu and Duan, {Kristina X.} and Mingxin Zhang and Suna Zhou and Qi Liu",
year = "2011",
month = "5",
day = "1",
doi = "10.1016/j.mehy.2011.01.036",
language = "English (US)",
volume = "76",
pages = "695--696",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "5",

}

TY - JOUR

T1 - Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy

AU - Wang, Jiansheng

AU - Zhang, Jia

AU - Sun, Junping

AU - Han, Jiangli

AU - Xi, Yutao

AU - Wu, Geru

AU - Duan, Kristina X.

AU - Zhang, Mingxin

AU - Zhou, Suna

AU - Liu, Qi

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Prostacyclin (PGI2) and its analogues protect from cardiovascular disease through pleiotropic effects such as vasodilation, inhibition of platelet aggregation, leukocyte adhesion, and vascular smooth muscle cell (VSMC) proliferation. Additionally, prostacyclin synthase (PGIS) and PGI2 also possess anti-cancer properties. As of late (2009-2010), numerous studies have identified the deleterious side-effects of chemotherapy on the cardiovascular system, which have been deemed as a serious clinical issue. Cardiomyocyte damage, induced by oxidative stress, is one of the clinical consequences caused by routine cancer chemotherapy. Previous studies indicate iloprost, a PGI2 analogue, can protect against doxorubicin-induced (DOX) cardiomyocyte injury in vitro and in vivo without compromising tumor suppression. Therefore, we hypothesize PGI2 can be used as a cardioprotective supplement to attenuate the damaging cardiac effects caused by the traditional cancer chemotherapy regimen.

AB - Prostacyclin (PGI2) and its analogues protect from cardiovascular disease through pleiotropic effects such as vasodilation, inhibition of platelet aggregation, leukocyte adhesion, and vascular smooth muscle cell (VSMC) proliferation. Additionally, prostacyclin synthase (PGIS) and PGI2 also possess anti-cancer properties. As of late (2009-2010), numerous studies have identified the deleterious side-effects of chemotherapy on the cardiovascular system, which have been deemed as a serious clinical issue. Cardiomyocyte damage, induced by oxidative stress, is one of the clinical consequences caused by routine cancer chemotherapy. Previous studies indicate iloprost, a PGI2 analogue, can protect against doxorubicin-induced (DOX) cardiomyocyte injury in vitro and in vivo without compromising tumor suppression. Therefore, we hypothesize PGI2 can be used as a cardioprotective supplement to attenuate the damaging cardiac effects caused by the traditional cancer chemotherapy regimen.

UR - http://www.scopus.com/inward/record.url?scp=79954424592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954424592&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2011.01.036

DO - 10.1016/j.mehy.2011.01.036

M3 - Article

VL - 76

SP - 695

EP - 696

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 5

ER -